ctDNA analysis predicts cancer recurrence and treatment efficacy in patients with resected stages I-III colon cancer. This large-scale, real-world study shows ctDNA positivity during the molecular residual disease (MRD) window correlates with significantly poorer disease-free survival (DFS). Patients who were ctDNA-positive at MRD and received adjuvant chemotherapy (ACT) demonstrated improved DFS compared to those monitored post-surgery. Additionally, patients remaining ctDNA-positive or converting from negative to positive faced substantially worse outcomes.
Journal Article by Cohen SA, Aushev VN (…) Kopetz S et 42 al. in Ann Surg
Copyright © 2025 The Author(s). Published by Wolters Kluwer Health, Inc.